Abstracts tagged "Biologics"

Abstract Number: 2929 • 2016 ACR/ARHP Annual Meeting
The Baseline Th17 Lymphocytes Level Is a Predictive Marker of Good Response to Biologics in Rheumatoid Arthritis
Sarah Salomon¹, Caroline Guignant², Pierre Morel³, Brigitte Gubler⁴, Patrice Fardellone⁵, Jean-Pierre Marolleau⁶ and Vincent Goeb⁷, ¹Rheumatology, University Hospital of Amiens, Amiens, France, ²Immunology Laboratory, University Hospital of Amiens, Amiens, France, ³Hematology, University Hospital of Amiens, Amiens, France, ⁴Immunology, University Hospital of Amiens, Amiens, France, ⁵Department of Rheumatology, Amiens University hospital, Amiens, France, ⁶hematology, University Hospital of Amiens, Amiens, France, ⁷Rheumatology, Amiens University Hospital, Amiens, France
Background/Purpose: In clinical daily practice, the response to biologic drugs is unpredictable in patients with rheumatoid arthritis (RA). Thus, there is a crucial need for…
Abstract Number: 17 • 2016 ACR/ARHP Annual Meeting
The Importance of Achieving Clinical Response to Treatment and Changes in Physical Ability and Quality of Life on Worker Productivity Outcomes in Rheumatoid Arthritis: Results from the British Society for Rheumatology Biologics Register
Sarah Leggett¹, Kimme L. Hyrich^1,2, Mark Lunt¹, Karen Walker-Bone³ and Suzanne M.M. Verstappen¹, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK, Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, ³University of Southampton, Arthritis Research UK / MRC Centre for Musculoskeletal Health and Work, Southampton, United Kingdom
Background/Purpose: It is well known that patients with RA experience health-related job loss, more days absent from work (i.e., absenteeism), and to a greater extent,…
Abstract Number: 1495 • 2016 ACR/ARHP Annual Meeting
Lipoprotein(a) Concentrations in Rheumatoid Arthritis on Biologic Therapy: Results from the Cardiovascular in Rheumatology [CARMA] Study Project
Maria Carmen Garcia-Gomez¹, Maria Auxiliadora Martin², Santos Castañeda³, Fernando Sánchez-Alonso⁴, Miren Uriarte Ecenarro⁵, Carlos González-Juanatey⁶, Romera-Baures Monserrat⁷, Santos-Rey Jose⁸, Jose A Pinto-Tasende⁹, Estefania QuesadaMasachs¹⁰, Jesús Tornero¹¹, Olga Martínez González¹², Tatiana Cobo-Ibáñez¹³, Eugenio Chamizo Carmona¹⁴, Sara Manrique-Arija¹⁵, Dolores Fábregas-Canales¹⁶, Federico Díaz-González¹⁷, Javier Llorca¹⁸, Miguel Angel González-Gay¹⁹ and CARMA Collaborative Group, ¹Rheumatology, Consorci Sanitari de Terrassa, Terrassa (Barcelona), Spain, ²Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ³Rheumatology, Hospital de la Princesa, IIS-IP, Madrid, Spain, ⁴Research Unit of Spanish Society of Rheumatology, Madrid, Spain, ⁵Donostia University Hospital, San Sebastian, Spain, ⁶Division or Cardiology, Hospital Lusus Augusti, Lugo, Spain, ⁷Rheumatology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat (Barcelona), Spain, ⁸Rheumatology, Hospital Virgen de la Salud, Toledo, Spain, ⁹Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruna, Spain, ¹⁰Rheumatology, Hospital Universitari Vall d’Hebron, Barcelona, Spain, ¹¹Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain, ¹²Rheumatology, HOSPITAL CLÍNICO UNIVERSITARIO DE SALAMANCA, Salamanca, Spain, ¹³Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ¹⁴Rheumatology, Hospital de Mérida, Mérida, Spain, ¹⁵Rheumatology, Hospital Carlos Haya, Malaga, Spain, ¹⁶Rheumatology, Hospital de Barbastro, Barbastro (Huesca), Spain, ¹⁷Rheumatology, Hospital Universitario de Canarias, S/C Tenerife, Spain, ¹⁸Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ¹⁹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain
Background/Purpose: Plasma concentrations of lipoprotein (a) [Lp(a)], a lipoprotein with proatherogenic and thrombogenic properties, have a strong genetic basis, although high concentrations of Lp(a) have…
Abstract Number: 1730 • 2016 ACR/ARHP Annual Meeting
Disease Progression Among Non-Achievers of Minimal Disease Activity in Psa Patients Treated with Infliximab or Golimumab
Dalton Sholter¹, Proton Rahman², Maqbool Sheriff³, Michel Zummer⁴, Suneil Kapur⁵, Philip Baer⁶, Michael Starr⁷, John Kelsall⁸, Emmanouil Rampakakis⁹, Eliofotisti Psaradellis¹⁰, Brendan Osborne¹¹, Karina Maslova¹², Cathy Tkaczyk¹¹, Francois Nantel¹³ and Allen J Lehman¹², ¹University of Alberta, Edmonton, AB, Canada, ²Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ³Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁴Rheumatology, Ch Maisonneuve-Rosemont, Montreal, QC, Canada, ⁵University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, ⁶Independent Rheumatology Practice, Scarborough, ON, Canada, ⁷Rheumatology, Mcgill University, Pointe-Claire,, QC, Canada, ⁸Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁹JSS Medical Research, St-Laurent, QC, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹²Janssen Inc., Toronto, ON, Canada, ¹³19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose : Early achievement of minimal disease activity (MDA) is recommended as a valid treat-to-target approach in psoriatic arthritis (PsA). The purpose of the current…
Abstract Number: 3092 • 2016 ACR/ARHP Annual Meeting
Predictive Factors for Better Outcome of Switching of Biologics for Patients with Rheumatoid Arthritis in Daily Clinical Practice
Kazuyoshi Saito¹, Kazuhisa Nakano², Shingo Nakayamada³, Satoshi Kubo⁴, Ippei Miyagawa¹, Shigeru Iwata⁵ and Yoshiya Tanaka⁶, ¹University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The First department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁵First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Eight biologics have been approved for rheumatoid arthritis (RA) in Japan. However, little is known regarding what to do when patients have an inadequate…
Abstract Number: 137 • 2016 ACR/ARHP Annual Meeting
Imaging Remission By Musculoskeletal Ultrasound Leads to a Better Functional Outcome – Results of the US Impera Study – US 7-Score Implementation Study in Early Rheumatoid Arthritis
Anne-Marie Glimm¹, Sarah Ohrndorf², Imma Fischer³, Johannes Strunk⁴, Wolfgang A. Schmidt⁵, Wolfgang Hartung⁶, Herbert Kellner⁷, Horst Sattler⁸, Gabriela Schmittat¹, GR Burmester⁹ and Marina Backhaus¹⁰, ¹Department of Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, ²Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ³Biostatistik Tuebingen, Tuebingen, Germany, ⁴Department of Rheumatology, Hospital 'Porz am Rhein', Academic Hospital of the University of Cologne, Cologne, Germany, ⁵Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ⁶Department of Rheumatology and Clinical Immunology, Asklepios Klinik Bad Abbach, Bad Abbach, Germany, ⁷Department of Internal Medicine – Rheumatologic Day Clinic, Krankenhaus Neuwittelsbach, Academic Hospital of Ludwig-Maximilians-University Munich, Munich, Germany, ⁸Internal Medicine and Rheumatology Practice, Bad Duerkheim, Bad Duerkheim, Germany, ⁹Charité – University Medicine Berlin, Berlin, Germany, ¹⁰Department of Rheumatology & Immunology, University Medicine Charit, Berlin, Germany
Background/Purpose: Novel treat-to-target strategies present new challenges to treatment monitoring in rheumatoid arthritis (RA). To compare functional outcomes in early RA patients monitored by standard…
Abstract Number: 1507 • 2016 ACR/ARHP Annual Meeting
Our Strategy of Preventing Tuberculosis (TB) in Patients with Rheumatic Diseases Under the Treatment with Biologic Dmards
Shinji Motojima¹, Tamao Nakashita², Akira Jibatake¹, Akira Yoshida¹ and Yoshiki Yamamoto¹, ¹Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan, ²Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa-city, Japan
Background/Purpose: According to the report by WHO, Japan is still in moderately-prevailing countries of TB. The annual incidence of TB in Japan is approximately 15/100,000,…
Abstract Number: 1732 • 2016 ACR/ARHP Annual Meeting
Articular and Axial Involvement Differences in Psoriatic Arthritis Patients Treated with Golimumab in Canadian Real-World Practice
Majed M. Khraishi¹, Proton Rahman², Alexander Tsoukas³, Suneil Kapur⁴, Milton F. Baker⁵, Niall Jones⁶, Michael Starr⁷, Emmanouil Rampakakis⁸, Eliofotisti Psaradellis⁹, Karina Maslova¹⁰, Francois Nantel¹¹, Allen J Lehman¹⁰, Cathy Tkaczyk¹² and Brendan Osborne¹², ¹Nexus Clinical Research, St Johns, NF, Canada, ²Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ³McGill University, Montreal, QC, Canada, ⁴University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, ⁵VIHA, Victoria, BC, Canada, ⁶University of Alberta, Edmonton, AB, Canada, ⁷McGill University, Pointe-Claire, QC, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a complex rheumatic disease with severity that ranges from mild to severe. The mild form of PsA can be referred…
Abstract Number: 3116 • 2016 ACR/ARHP Annual Meeting
Risk of Infections in Juvenile Idiopathic Arthritis Patients Treated with Biologic Agentsand/or Methotrexate: Results from Pharmachild Registry
Gabriella Giancane¹, Joost Swart², Francesca Bovis², Elio Castagnola², Andreas Groll², Gerd Horneff², Hans-Iko Huppertz², Daniel J. Lovell², Tom Wolfs², Michaël Hofer², Ekaterina Alexeeva², Violeta Vladislava Panaviene², Susan Nielsen², Jordi Anton², Florence Uettwiller², Valda Stanevicha², Maria Trachana², Denise Pires Marafon³, Constantin Ailioaie², Elena Tsitsami², Sylvia S.M. Kamphuis², Troels Herlin², Pavla Dolezalová³, Gordana Susic², Berit Flato², Flavio Sztajnbok², Angela Pistorio¹, Alberto Martini², Nico Wulffraat² and Nicolino Ruperto², ¹Pediatria II, Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, ²Istituto Giannina Gaslini, Genoa, Italy, ³Istituto Giannina Gaslini, genoa, Italy
Background/Purpose: Pharmachild is an international registry involving over 100 the Paediatric Rheumatology INternational Trials Organisation (PRINTO)/ the Paediatric Rheumatology European Society (PRES) centres in 38 countries. The registry was set up to evaluate long term safety and efficacy…
Abstract Number: 13L • 2015 ACR/ARHP Annual Meeting
Safety and Efficacy of E6011, an Anti-Fractalkine Monoclonal Antibody, in a First-in-Patient Phase 1/2 Study in Rheumatoid Arthritis
Yoshiya Tanaka¹, Tsutomu Takeuchi², Hisanori Umehara³, Toshihiro Nanki⁴, Hideto Akama⁵, Nobuyuki Yasuda⁵, Fumitoshi Tago⁵, Makoto Kawakubo⁵, Seiichiro Hojo⁵, Tetsu Kawano⁶ and Toshio Imai⁶, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Dept. of Internal Medicine, School of Medicine Keio University, Tokyo, Japan, ³Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁴School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, ⁵EISAI Co. Ltd., Tokyo, Japan, ⁶KAN Research Institute, Inc., Kobe, Japan
Background/Purpose: Fractalkine (CX3CL1, designated as FKN hereafter) is the sole member of the CX3C-chemokine which leads to dual actions, chemotaxis and cell adhesion for leukocytes…
Abstract Number: 450 • 2015 ACR/ARHP Annual Meeting
Use of Tofacitinib in a Real World Setting: Clinical Features in a Cohort of Patients Using the Database Jointman Compared to a Published Clinical Trial
Sergio Schwartzman¹, Keith Knapp², Gary Craig³, Karen Ferguson⁴ and Howard Kenney⁵, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Arthritis Northwest, Spokane, WA, ³Discus Analytics, Inc., Spokane, WA, ⁴Arthritis Northwest PLLC., Spokane, WA, ⁵Rheumatology, Arthritis Northwest, Spokane, WA
Background/Purpose: It is well accepted that patients studied in pharmaceutically sponsored clinical trials do not always represent the types of patients seen in clinical practice. …
Abstract Number: 1225 • 2015 ACR/ARHP Annual Meeting
Long-Term Use of Biological Therapy and Discontinuation Rates in Rheumatoid Arthritis – Real World Patient Data
Laurent Chanroux, Joan Casellas and Fara Mboge, Therapy Watch, Research Partnership, London, United Kingdom
Background/Purpose: Biologics (bDMARDs) have been shown to control disease progression in RA however there is still no cure for the disease and in many cases…
Abstract Number: 2642 • 2015 ACR/ARHP Annual Meeting
Patient Reported Outcome Assessment of Rheumatoid Arthritis Patients Experience with IV Administered Biologic Therapy
Norman B. Gaylis¹, Joanne Sagliani¹, Danny Tuccitto², Shawn Black³, Kehzen Tang⁴, Raphael Dehoratius^3,5 and Dennis Parenti³, ¹Arthritis & Rheumatic Disease Specialties, Aventura, FL, ²AARDS Research, Inc, Aventura, FL, ³Janssen Scientific Affairs, LLC, Horsham, PA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Kimmel School of Medicine, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Patient-reported outcomes (PRO) are used to assess patient related benefit in clinical trials. Rheumatoid arthritis (RA) patients are equally receptive to intravenous (IV) or…
Abstract Number: 455 • 2015 ACR/ARHP Annual Meeting
Predictors of Real-World Treatment Sustainability in RA Patients Treated with Abatacept in Canada: Implications for Routine Care
Janet E. Pope¹, Emmanouil Rampakakis² and John S. Sampalis³, ¹University of Western Ontario, London, ON, Canada, ²JSS Medical Research, St-Laurent, QC, Canada, ³Clinical Research, JSS Medical Research, Westmount, QC, Canada
Background/Purpose: Treatment sustainability can measure drug effectiveness and encompasses drug effectiveness, safety, and compliance. Recent data suggest that differences in retention may exist between biologic…
Abstract Number: 1408 • 2015 ACR/ARHP Annual Meeting
Cogan Syndrome: Differential Response to Biologic Agents and Role of PET-CT in the Increased Diagnosis of Aortitis
Bahtiyar Toz¹, Burak Erer², Sevil Kamali², Ilknur Tugal-tutkun³, Lale Ocal² and Ahmet Gul⁴, ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ⁴Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine,, Istanbul, Turkey
Background/Purpose: Cogan syndrome (CS) is a rare inflammatory disorder typically characterized by interstitial keratitis and audiovestibular symptoms, and patients may also develop other inflammatory ocular…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.